Key statistics
On Friday, Eledon Pharmaceuticals Inc (ELDN:NAQ) closed at 2.02, 49.63% above the 52 week low of 1.35 set on Nov 21, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 2.02 |
|---|---|
| High | 2.15 |
| Low | 2.00 |
| Bid | 1.97 |
| Offer | 2.06 |
| Previous close | 2.01 |
| Average volume | 488.37k |
|---|---|
| Shares outstanding | 79.24m |
| Free float | 78.38m |
| P/E (TTM) | -- |
| Market cap | 160.06m USD |
| EPS (TTM) | -0.0993 USD |
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
More ▼
Announcements
- Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
- Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium
- Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook
- Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference
- Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
- Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results
- Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
- Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
- Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology’s Kidney Week 2025 Annual Meeting
- Eledon Pharmaceuticals to Present at Guggenheim Second Annual Healthcare Innovation Conference
More ▼
